Matthew Hickman

Matthew Hickman

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Matthew Hickman

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The Lancet Global Health
Verified
Journal Article
Open access
LDLouisa Degenhardt
Louisa Degenhardt
APAmy Peacock
Amy Peacock
SCSamantha Colledge
Samantha Colledge
Janni LeungJanni Leung
Janni Leung
JGJason Grebely
Jason Grebely
SLSarah Larney
Sarah Larney
Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15-64 years; sociodemographic characteristics of and risk factors for people who inject drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID. Consistent with the GATHER and PRISMA guidelines and without language restrictions, we systematically searched peer-reviewed databases (MEDLINE, Embase, and PsycINFO; articles published since 2008, latest searches in June, 2017), searched the grey literature (websites and databases, searches between April and August, 2016), and disseminated data requests to international experts and agencies (requests sent in October, 2016). We searched for data on IDU prevalence, characteristics of PWID, including gender, age, and sociodemographic and risk characteristics, and the prevalence of HIV, HCV, and HBV among PWID. Eligible data on prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where multiple estimates were available, pooled for each country via random effects meta-analysis. So too were eligible data on percentage of PWID who were female; younger than 25 years; recently homeless; ever arrested; ever incarcerated; who had recently engaged in sex work, sexual risk, or injecting risk; and whose main drugs injected were opioids or stimulants. We generated regional and global estimates in line with previous global reviews. We reviewed 55 671 papers and reports, and extracted data from 1147 eligible records. Evidence of IDU was recorded in 179 of 206 countries or territories, which cover 99% of the population aged 15-64 years, an increase of 31 countries (mostly in sub-Saharan Africa and the Pacific Islands) since a review in 2008. IDU prevalence estimates were identified in 83 countries. We estimate that there are 15·6 million (95% uncertainty interval [UI] 10·2-23·7 million) PWID aged 15-64 years globally, with 3·2 million (1·6-5·1 million) women and 12·5 million (7·5-18·4 million) men. Gender composition varied by location: women were estimated to comprise 30·0% (95% UI 28·5-31·5) of PWID in North America and 33·4% (31·0-35·6) in Australasia, compared with 3·1% (2·1-4·1) in south Asia. Globally, we estimate that 17·8% (10·8-24·8) of PWID are living with HIV, 52·3% (42·4-62·1) are HCV-antibody positive, and 9·0% (5·1-13·2) are HBV surface antigen positive; there is substantial geographic variation in these levels. Globally, we estimate 82·9% (76·6-88·9) of PWID mainly inject opioids and 33·0% (24·3-42·0) mainly inject stimulants. We estimate that 27·9% (20·9-36·8) of PWID globally are younger than 25 years, 21·7% (15·8-27·9) had recently (within the past year) experienced homelessness or unstable housing, and 57·9% (50·5-65·2) had a history of incarceration. We identified evidence of IDU in more countries than in 2008, with the new countries largely consisting of low-income and middle-income countries in Africa. Across all countries, a substantial number of PWID are living with HIV and HCV and are exposed to multiple adverse risk environments that increase health harms. Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, Open Society Foundation, World Health Organization, the Global Fund, and UNAIDS.

1 November 2008 in The Lancet
Verified
Journal Article
Closed access
BMBradley M Mathers
Bradley M Mathers
LDLouisa Degenhardt
Louisa Degenhardt
BPBenjamin Phillips
Benjamin Phillips
LWLucas Wiessing
Lucas Wiessing
MHMatthew Hickman
Matthew Hickman
RMRichard P Mattick
Richard P Mattick

10 May 2018 in Addiction
Verified
Journal Article
Open access
PDF file
APAmy Peacock
Amy Peacock
Janni LeungJanni Leung
Janni Leung
SLSarah Larney
Sarah Larney
SCSamantha Colledge
Samantha Colledge
MHMatthew Hickman
Matthew Hickman
LDLouisa Degenhardt
Louisa Degenhardt
Aims: This review provides an up‐to‐date curated source of information on alcohol, tobacco and illicit drug use and their associated mortality and burden of disease. Limitations in the data are also discussed, including how these can be addressed in the future.Methods: Online data sources were identified through expert review. Data were obtained mainly from the World Health Organization, United Nations Office on Drugs and Crime and Institute for Health Metrics and Evaluation.Results: In 2015, the estimated prevalence among the adult population was 18.4% for heavy episodic alcohol use (in the past 30 days); 15.2% for daily tobacco smoking; and 3.8, 0.77, 0.37 and 0.35% for past‐year cannabis, amphetamine, opioid and cocaine use, respectively. European regions had the highest prevalence of heavy episodic alcohol use and daily tobacco use. The age‐standardized prevalence of alcohol dependence was 843.2 per 100 000 people; for cannabis, opioids, amphetamines and cocaine dependence it was 259.3, 220.4, 86.0 and 52.5 per 100 000 people, respectively. High‐income North America region had among the highest rates of cannabis, opioid and cocaine dependence. Attributable disability‐adjusted life‐years (DALYs) were highest for tobacco smoking (170.9 million DALYs), followed by alcohol (85.0 million) and illicit drugs (27.8 million). Substance‐attributable mortality rates were highest for tobacco smoking (110.7 deaths per 100 000 people), followed by alcohol and illicit drugs (33.0 and 6.9 deaths per 100 000 people, respectively). Attributable age‐standardized mortality rates and DALYs for alcohol and illicit drugs were highest in eastern Europe; attributable age‐standardized tobacco mortality rates and DALYs were highest in Oceania.Conclusions: In 2015 alcohol use and tobacco smoking use between them cost the human population more than a quarter of a billion disability‐adjusted life years, with illicit drugs costing further tens of millions. Europeans suffered proportionately more, but in absolute terms the mortality rate was greatest in low‐ and middle‐income countries with large populations and where the quality of data was more limited. Better standardized and rigorous methods for data collection, collation and reporting are needed to assess more accurately the geographical and temporal trends in substance use and its disease burden.

1 October 2019 in The Lancet
Verified
Journal Article
Closed access
LDLouisa Degenhardt
Louisa Degenhardt
JGJason Grebely
Jason Grebely
JSJack Stone
Jack Stone
MHMatthew Hickman
Matthew Hickman
PVPeter Vickerman
Peter Vickerman
SLSarah Larney
Sarah Larney

4 November 2010 in Addiction
Verified
Journal Article
Closed access
PDF file
LDLouisa Degenhardt
Louisa Degenhardt
CBChiara Bucello
Chiara Bucello
BMBradley Mathers
Bradley Mathers
CBChristina Briegleb
Christina Briegleb
HAHammad Ali
Hammad Ali
JMJennifer McLaren
Jennifer McLaren

1 March 2010 in The Lancet
Verified
Journal Article
Closed access
BMBradley M Mathers
Bradley M Mathers
LDLouisa Degenhardt
Louisa Degenhardt
HAHammad Ali
Hammad Ali
LWLucas Wiessing
Lucas Wiessing
MHMatthew Hickman
Matthew Hickman
Steffanie StrathdeeSteffanie Strathdee
Steffanie Strathdee